These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

728 related items for PubMed ID: 23305158

  • 1. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.
    Mueck W, Kubitza D, Becka M.
    Br J Clin Pharmacol; 2013 Sep; 76(3):455-66. PubMed ID: 23305158
    [Abstract] [Full Text] [Related]

  • 2. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.
    Parasrampuria DA, Mendell J, Shi M, Matsushima N, Zahir H, Truitt K.
    Br J Clin Pharmacol; 2016 Dec; 82(6):1591-1600. PubMed ID: 27530188
    [Abstract] [Full Text] [Related]

  • 3. Perpetrator effects of ciclosporin (P-glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers.
    Brings A, Lehmann ML, Foerster KI, Burhenne J, Weiss J, Haefeli WE, Czock D.
    Br J Clin Pharmacol; 2019 Jul; 85(7):1528-1537. PubMed ID: 30912163
    [Abstract] [Full Text] [Related]

  • 4. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin.
    Gouin-Thibault I, Delavenne X, Blanchard A, Siguret V, Salem JE, Narjoz C, Gaussem P, Beaune P, Funck-Brentano C, Azizi M, Mismetti P, Loriot MA.
    J Thromb Haemost; 2017 Feb; 15(2):273-283. PubMed ID: 27893182
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
    Hellwig T, Gulseth M.
    Ann Pharmacother; 2013 Nov; 47(11):1478-87. PubMed ID: 24259602
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry.
    Gong IY, Mansell SE, Kim RB.
    Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):164-70. PubMed ID: 22958812
    [Abstract] [Full Text] [Related]

  • 10. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ, Lagas JS, Rosing H, Schellens JH, Beijnen JH, Schinkel AH.
    Int J Cancer; 2013 May 15; 132(10):2439-47. PubMed ID: 23090875
    [Abstract] [Full Text] [Related]

  • 11. Physiologically-Based Pharmacokinetic Modeling for the Prediction of a Drug-Drug Interaction of Combined Effects on P-glycoprotein and Cytochrome P450 3A.
    Otsuka Y, Choules MP, Bonate PL, Komatsu K.
    CPT Pharmacometrics Syst Pharmacol; 2020 Nov 15; 9(11):659-669. PubMed ID: 33030266
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.
    Dresser GK, Spence JD, Bailey DG.
    Clin Pharmacokinet; 2000 Jan 15; 38(1):41-57. PubMed ID: 10668858
    [Abstract] [Full Text] [Related]

  • 13. Application of Static Modeling --in the Prediction of In Vivo Drug-Drug Interactions between Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition Studies.
    Cheong EJ, Goh JJ, Hong Y, Venkatesan G, Liu Y, Chiu GN, Kojodjojo P, Chan EC.
    Drug Metab Dispos; 2017 Mar 15; 45(3):260-268. PubMed ID: 28053220
    [Abstract] [Full Text] [Related]

  • 14. Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4.
    Wang E, Lew K, Barecki M, Casciano CN, Clement RP, Johnson WW.
    Chem Res Toxicol; 2001 Dec 15; 14(12):1596-603. PubMed ID: 11743742
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
    Mouly SJ, Matheny C, Paine MF, Smith G, Lamba J, Lamba V, Pusek SN, Schuetz EG, Stewart PW, Watkins PB.
    Clin Pharmacol Ther; 2005 Dec 15; 78(6):605-18. PubMed ID: 16338276
    [Abstract] [Full Text] [Related]

  • 18. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.
    Frost CE, Byon W, Song Y, Wang J, Schuster AE, Boyd RA, Zhang D, Yu Z, Dias C, Shenker A, LaCreta F.
    Br J Clin Pharmacol; 2015 May 15; 79(5):838-46. PubMed ID: 25377242
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic Drug Interactions of an Orally Available TRH Analog (Rovatirelin) With a CYP3A4/5 and P-Glycoprotein Inhibitor (Itraconazole).
    Kobayashi K, Abe Y, Kawai A, Furihata T, Endo T, Takeda H.
    J Clin Pharmacol; 2020 Oct 15; 60(10):1314-1323. PubMed ID: 32459872
    [Abstract] [Full Text] [Related]

  • 20. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.
    Bruyère A, Declèves X, Bouzom F, Ball K, Marques C, Treton X, Pocard M, Valleur P, Bouhnik Y, Panis Y, Scherrmann JM, Mouly S.
    Mol Pharm; 2010 Oct 04; 7(5):1596-607. PubMed ID: 20604570
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.